These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27177492)

  • 1. Severe eosinophilic asthma and mepolizumab.
    Walsh GM
    Lancet Respir Med; 2016 Jul; 4(7):528-529. PubMed ID: 27177492
    [No Abstract]   [Full Text] [Related]  

  • 2. Mepolizumab, quality of life, and severe eosinophilic asthma.
    Pavord ID
    Lancet Respir Med; 2017 May; 5(5):362-363. PubMed ID: 28395935
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
    Howarth P; Quirce S; Papi A; Israel E; Mallett S; Bates S; Yancey S; Albers FC; Kwon N
    Allergy; 2020 Aug; 75(8):2085-2088. PubMed ID: 32147844
    [No Abstract]   [Full Text] [Related]  

  • 5. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
    Cormier M; Chaboillez S; Lemiere C
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
    [No Abstract]   [Full Text] [Related]  

  • 6. Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use.
    Albers FC; Hozawa S; Bratton DJ; Yancey SW; Prazma CM; Humbert M; Liu MC
    Allergy; 2020 Apr; 75(4):942-946. PubMed ID: 31520471
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
    Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
    Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia.
    Sato H; Miyata Y; Inoue H; Tanaka A; Sagara H
    J Investig Allergol Clin Immunol; 2021 Oct; 31(5):459-460. PubMed ID: 33502319
    [No Abstract]   [Full Text] [Related]  

  • 10. Biomarkers for severe eosinophilic asthma.
    Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
    J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab prefilled syringe for the treatment of severe eosinophilic asthma: focus on the pediatric population.
    Revier MD; Geng B
    Expert Rev Respir Med; 2022 Aug; 16(8):857-865. PubMed ID: 35916083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 13. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
    Strauss RA; Jawhari N
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
    [No Abstract]   [Full Text] [Related]  

  • 14. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract]   [Full Text] [Related]  

  • 15. Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma.
    Nixon R; Despiney R; Pfeffer P
    BMJ Case Rep; 2020 Feb; 13(2):. PubMed ID: 32086326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
    Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma.
    Yancey SW; Ortega HG; Keene ON; Mayer B; Gunsoy NB; Brightling CE; Bleecker ER; Haldar P; Pavord ID
    J Allergy Clin Immunol; 2017 Apr; 139(4):1167-1175.e2. PubMed ID: 27726946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy.
    Howarth P; Chupp G; Nelsen LM; Bradford ES; Bratton DJ; Smith SG; Albers FC; Brusselle G; Bachert C
    J Allergy Clin Immunol; 2020 Jun; 145(6):1713-1715. PubMed ID: 32084443
    [No Abstract]   [Full Text] [Related]  

  • 19. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
    Castro M; Bacharier LB
    Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.